Tevogen uses its ExacTcell™ platform to generate off‑the‑shelf, genetically unmodified CD8+ cytotoxic T‑cell therapies that target disease‑specific antigens presented by a single HLA molecule. Leveraging AI‑driven Tevogen.AI for peptide‑HLA prediction, the company produces scalable, allogeneic T‑cell products designed for affordable treatment of infectious diseases, cancers and neurological disorders.
Funding
$14M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cellular immunotherapies are often expensive, require patient-specific manufacturing, and rely on genetically modified cells, limiting scalability and access for large patient populations with infectious diseases, cancer, or neurological disorders.
Solution
Tevogen leverages its ExacTcell™ platform to produce off‑the‑shelf, genetically unmodified CD8+ cytotoxic T lymphocytes that are precisely targeted to disease‑specific antigens presented by a single HLA molecule. By selecting naturally occurring T‑cell receptors and expanding them in a commercial‑scale, donor‑efficient process, the company creates personalized yet allogeneic T‑cell products that can be manufactured at scale and priced for broad accessibility. Complementary AI‑driven Tevogen.AI tools predict high‑confidence peptide‑HLA targets, accelerating candidate selection and reducing development risk. The combined biologic and computational approach enables rapid development of therapies for viral infections, virus‑induced cancers, and non‑viral malignancies while maintaining safety through antigen specificity.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immunotherapies for infectious diseases, cancers, or neurological conditions, as well as clinical research organizations seeking scalable, off‑the‑shelf T‑cell products.
Features
- ExacTcell™: highly purified, target‑specific CD8+ CTLs derived from naturally occurring, genetically unmodified T cells
- Single‑HLA restriction per product, ensuring precise peptide‑HLA recognition and minimizing off‑target effects
- Commercial‑scale manufacturing process delivering multiple doses per donor, with a second‑generation TCR‑T platform to increase dose yield
- AI‑powered PredicTcell™ model (Tevogen.AI) that predicts proteome‑wide peptide‑HLA interactions with >90% recall and ~48% precision
- Continuous learning loop integrating literature mining, wet‑lab validation, and production AI agents to refine target predictions
- Off‑the‑shelf, allogeneic product format eliminates patient‑specific cell manufacturing and reduces time to treatment
- Broad therapeutic applicability across virology (e.g., COVID‑19, Long COVID), oncology, and neurology